Bevacizumab is a 149 kDa full-length, bivalent monoclonal antibody targeting VEGF-A, designed to inhibit angiogenesis and starve solid tumors of their blood supply. It undergoes proteolytic catabolism and is recycled via FcRn binding in endothelial cells, contributing to a long systemic half-life of approximately 20 days post-intravenous infusion. Due to cost-effectiveness and comparable efficacy, off-label use of Bevacizumab has increased, particularly in wet AMD treatment. Pharmacokinetic (PK) assays are essential for characterizing in vivo drug behavior, projecting human PK, assessing PK/PD relationships in animal models, determining safety margins, and establishing an appropriate starting or efficacious dose. The FDA mandates that PK assays be precise, accurate, and robust for reliable Bevacizumab quantification. PK assays for Bevacizumab were developed on different immunoassay technology platforms ELISA and MSD to achieve an appropriate sensitivity. Given the variability in endogenous VEGF levels among patients, a sandwich ELISA was developed for Avastin and its biosimilars using two commercially available A validated PK bridging ELISA was established with a lower limit of quantification (LLOQ) of 10 ng/mL and an upper limit of quantification (ULOQ) of 220 ng/mL. PK assay optimized using MSD ECLIA demonstrated approximately 20-fold higher sensitivity compared to Sandwich Strep-Biotin detection ELISA with Inhibitory Anti-id antibody matched pair. This study highlights the usefulness of evaluating the performance of different immunoassay platforms at an early stage in the PK assay development process to aid in the selection of the best fit-for-purpose technology platform and sample pretreatment steps.
1. Biologic medicines have transformed the therapeutic landscape for many chronic and severe diseases by enabling highly specific targeting of disease pathways. Biologic products encompass a broad ...
Precise quantitative determination of Vascular Endothelial Growth Factor (VEGF) in human plasma is critical for pharmacodynamic (PD) evaluation of anti-VEGF therapeutics. In this study, we developed and optimized two immunoassay platforms, including the enzyme-linked immunosorbent assay (ELISA) and the Meso Scale Discovery (MSD), for estimating VEGF. A direct sandwich ELISA was validated to quantify pharmacodynamic biomarker VEGF in human plasma using the Human VEGF Quantikine Kit, demonstrating a quantification range of 62.5–2000.0 pg/mL and a sensitivity of 47.5 pg/mL. In parallel, a sandwich electrochemiluminescence (ECL) assay was developed using the V-PLEX Plus Human VEGF Kit on the MSD platform, achieving a lower quantification range of 7.7–562.0 pg/mL. Comparative analysis revealed that MSD ECL detection with Sulfo Tag labeling outperformed traditional colorimetric ELISA in terms of signal amplification and dynamic range, making it a valuable tool for PD biomarker analysis. Findings underscore the importance of early platform selection to ensure robust, fit-for-purpose biomarker quantification for clinical pharmacology studies and regulatory submissions.
29 January 2026 in Biochemistry and Biophysics Reports
Bevacizumab (BVZ) is an anti-vascular Endothelial Growth Factor-A monoclonal antibody (mAb) widely used in oncology and ophthalmology indications globally. Accurate quantification of mAbs in biological fluids is an essential prerequisite for determining pharmacokinetic (PK) parameters to assess the relationship between drug exposure and response. We developed and evaluated PK assays for BVZ in human serum using enzyme-linked immunosorbent assays (ELISA) and Meso Scale Discovery (MSD) immunoassay platforms to assess sensitivity and performance. The ELISA method, employing a Streptavidin-Biotin detection system with anti-idiotypic antibodies, demonstrated five times greater sensitivity than the conventional horseradish peroxidase-based ELISA format. The validated PK bridging ELISA achieved a quantification range of 10–220 ng/mL, extendable to 5000 ng/mL via dilution. In contrast, the MSD assay utilized electrochemiluminescence detection with Sulfo Tag labeling, offering a 20-fold higher sensitivity and detecting BVZ at concentrations as low as 500 pg/mL. This parallel evaluation concluded that ELISA is suitable for routine PK analysis due to its robustness and cost-efficiency. At the same time, MSD is advantageous for detecting BVZ at low concentrations in early-phase clinical trials and ophthalmic applications where serum levels are minimal.